Perspectives
Telehealth: an opportunity to increase access to early medical abortion for Australian women
Danielle Mazza,
Seema Deb, Asvini Subasinghe,
Corresponding Author
Danielle Mazza
Monash University, Melbourne, VIC
Search for more papers by this authorDanielle Mazza,
Seema Deb, Asvini Subasinghe,
Corresponding Author
Danielle Mazza
Monash University, Melbourne, VIC
Search for more papers by this authorPodcast with Danielle Mazza available at mja.com.au/podcasts
No abstract is available for this article.
References
- 1Mazza D, Burton G, Wilson S, et al. Medical abortion. Aust J Gen Pract 2020; 49: 324–330.
- 2Subasinghe AK, Deb S, Mazza D. Primary care providers’ knowledge, attitudes and practices of medical abortion: a systematic review. BMJ Sex Reprod Health 2019; https://doi.org/10.1136/bmjsrh-2019-200487 [Epub ahead of print].
- 3Deb S, Subasinghe AK, Mazza D. Providing medical abortion in general practice: General practitioner insights and tips for future providers. Aust J Gen Pract 2020; 49: 331–337.
- 4Newton D, Bayly C, McNamee K, et al. How do women seeking abortion choose between surgical and medical abortion? Perspectives from abortion service providers. Aust N Z J Obstet Gynaecol 2016; 56: 523–529.
- 5LaRoche KJ, Wynn LL, Foster AM. “We've got rights and yet we don't have access”: Exploring patient experiences accessing medication abortion in Australia. Contraception 2020; 101: 256–260.
- 6 Marie Stopes Australia. Situational report: sexual and reproductive health rights in Australia. A request for collaboration and action to maintain contraceptive and abortion care throughout the SARS-CoV-2/COVID-19 pandemic. https://resources.mariestopes.org.au/SRHRinAustralia.pdf (viewed June 2020).
- 7Ireland S, Belton S, Doran F. “I didn't feel judged”: exploring women's access to telemedicine abortion in rural Australia. J Prim Health Care 2020; 12: 49–56.
- 8Hyland P, Raymond EG, Chong E. A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months. Aust N Z J Obstet Gynaecol 2018; 58: 335–340.
- 9Endler M, Lavelanet A, Cleeve A, et al. Telemedicine for medical abortion: a systematic review. BJOG 2019; 126: 1094–1102.
- 10Aiken ARA, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. BMJ 2017; 357: j2011.
- 11Kidd M. Australia's primary care COVID-19 response. Aust J Gen Pract 2020; https://doi.org/10.31128/ajgp-covid-02 [Epub ahead of print].
- 12 Australian Government, Department of Health. Telehealth changes improve remote Australians’ access to a doctor 2019 [media release]. 29 Oct 2019. https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/telehealth-changes-improve-remote-australians-access-to-a-doctor (viewed June 2020).
- 13 Australian Government, Department of Health. Continuous care with telehealth stage seven [media release]. 10 July 2020. https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/continuous-care-with-telehealth-stage-seven (viewed July 2020).
- 14 Women's Sexual and Reproductive Health COVID-19 Coalition. Evidence-based practice and policy recommendations regarding early medical abortion: a consensus statement. SPHERE NHMRC Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care, 2020. https://3fe3eaf7-296b-470f-809a-f8eebaec315a.filesusr.com/ugd/410f2f_accfc0aeceaf4e7cb5cb0948a1248f27.pdf (viewed June 2020).
- 15 RADAR. Mifepristone and misoprostol (MS-2 Step) composite pack: use extended to 63 days’ gestation. Sydney: NPS MedicineWise, 2015. www.nps.org.au/radar/articles/mifepristone-and-misoprostol-ms-2-step-composite-pack-use-extended-to-63-days-gestation (viewed June 2020).
- 16Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception 2019; 99: 77–86.
- 17Costescu D, Guilbert E, Wagner MS, et al. Induced abortion: updated guidance during pandemics and periods of social disruption. Society of Obstetricians and Gynaecologists of Canada, 2020. https://sogc.org/common/Uploaded%20files/Induced%20Abortion%20-%20Pandemic%20Guidance%20-%20FINAL.PDF (viewed June 2020).
- 18 US Food and Drug Administration. Mifeprex (mifepristone) information. FDA, 2018. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information (viewed June 2020).
- 19 Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection and abortion care. Information for healthcare professionals. London: RCOG, 2020. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-abortion/ (viewed June 2020).
- 20Raymond EG, Grossman D, Mark A, et al. No-test medication abortion: a sample protocol for increasing access during a pandemic and beyond. Contraception 2020; 101: 361–366.
- 21 Royal Australian and New Zealand College of Obstetricians and Gynaecologists. COVID-19: anti D and abortion. RANZCOG, 2020. https://ranzcog.edu.au/news/covid-19-anti-d-and-abortion (viewed May 2020).
